Eckert & Ziegler Strahlen- und Medizintechnik AG announced that to expand its manufacturing capacities, Eckert & Ziegler plans to invest around ?10 million in its own site in Wilmington, MA. Eckert & Ziegler is thus positioning itself as an important supplier of lutetium-177 in the rapidly growing radioligand therapy market.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.86 EUR | -4.22% | +1.91% | +11.04% |
06-25 | German Stocks Fall Tuesday | DJ |
06-25 | Eckert & Ziegler Unit Gets 'Encouraging' Feedback from US FDA for Lead Diagnostic | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+11.04% | 1.02B | |
+2.11% | 7.37B | |
-12.41% | 4.29B | |
+1.31% | 3.18B | |
+17.42% | 2.31B | |
+7.78% | 941M | |
-39.11% | 925M | |
-57.14% | 676M | |
-28.72% | 633M | |
-36.34% | 623M |
- Stock Market
- Equities
- EUZ Stock
- News Eckert & Ziegler SE
- Eckert & Ziegler Strahlen- und Medizintechnik AG Announces Plans to Invest Around ? 10 Million in its Own Site in Wilmington